Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer

Summary

Research Hypothesis: icotinib administered in combination with gemcitabine has an acceptable safety profile in subjects with locally advanced, unresectable or metastatic pancreatic adenocarcinoma.The primary objective is to determine the safety profile of icotinib in combination with gemcitabine in subjects with locally advanced, unresectable or metastatic pancreatic adenocarcinoma.

Timeline

Start

2014-10

Primary completion

2016-01

Completion

2016-10

Drugs

Indications